Kornimate/medical-research-clean huggingface dataset:
the effect of brain stimulation (tdcs) in food cravings control in overweight/obese women

Conditions: Obesity

Summary: this study is a randomized clinical trial to test the effect of a type of non-invasive brain stimulation on the response to a behavioral intervention designed to enhance cognitive control over food cravings in obese and overweight women. the brain stimulation is called transcranial direct current stimulation (tdcs). all eligible participants will engage in a behavioral intervention known to enhance control over food cravings and will be randomly assigned to receive either tdcs or sham stimulation to the prefrontal cortex of the brain.

this study is a randomized clinical trial to test the effect of a type of non-invasive brain stimulation on the response to a behavioral intervention designed to enhance cognitive control over food cravings in obese and overweight women. the brain stimulation is called transcranial direct current stimulation (tdcs) which is a form of stimulation that delivers a low amplitude electrical current to the brain via the scalp (i.e. trans-cranial) to modify brain activity. all eligible participants will engage in a behavioral intervention (go-no go task), known to enhance control over food cravings, and will be randomly assigned to receive either tdcs or sham stimulation to the right prefrontal cortex of the brain during 8 20-min daily sessions. primary outcome: score changes in eating behaviors scales (yfas and tfeq), scales will be applied at baseline and at the end of the 8 brain stimulation sessions. secondary outcomes: changes in diet, brain function (brain mri/mrs) other outcomes: food cravings scales and impulse control scales and cognitive function.

Eligibility criteria:
inclusion criteria: bmi between 28 and 40 kg/m2 high scores in the yale-food addiction-scale right-handed exclusion criteria: * history of anorexia nervosa or bulimia or binge eating disorder * any contraindication to undergo mri * use of psychotropic medications and/or opiate pain medications. * current or past alcohol or drug abuse problem or smoking * pregnancy * current use of weight loss medication or currently participating in a weight loss program. * history of seizures, epilepsy or factors/medications associated with lowered seizure threshold. * history of brain disease or major neurological disorder or mental disorder * history of brain surgery or history of loss of consciousness \>15 min * history of major gastrointestinal surgery including weight loss surgery * history of endocrine imbalances including diabetes, thyroid disease, cushing's disease, metabolic syndrome and polycystic ovary.

Keywords: food cravings neuromodulation brain cognitive control tdcs prefrontal cortex mri food addiction
efficacy study of switching to a lutenizing hormone-releasing hormone (lhrh) antagonist from a lhrh agonist to treat progressive castrate resistant prostate cancer (crpc)

Conditions: Prostate Neoplasm

Summary: men with castrate resistant prostate cancer who are switched from a luteinizing hormone-releasing hormone (lhrh) antagonists from a lhrh agonist will experience a fall in prostate-specific antigen (psa).

to determine the proportion of patients with castrate resistant prostate cancer who have a psa decline of ≥50% from baseline psa when switched from an lhrh agonist to an lhrh antagonist.

Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of the prostate * currently receiving lhrh agonist * anti-androgen oral therapy is permitted but will be discontinued upon enrollment * psa \> 2 ng/ml * rising psa despite lhrh agonist * patients may or may not have clinical evidence off metastases. if metastases are present, they must be asymptomatic and in bone or lymph node only * prior chemotherapy allowed * ecog performance status 0-1 exclusion criteria: * patients with a history of other active malignancies, except: adequately treated non-melanoma skin cancer, superficial bladder cancer, or other solid tumours curatively treated with no evidence of disease for ≥ 3 years. * other serious illness, psychiatric or medical condition that would not permit the patient to be managed according to the protocol including: i)significant cardiovascular condition including but not limited to: uncontrolled hypertension, unstable angina, significant congestive heart failure or myocardial infarction, deep venous thrombosis, pulmonary embolus or cerebrovascular attack within the last 6 months. ii) history of significant neurological disorder that would impair the ability to obtain consent

Keywords: castrate resistance psa progression lhrh antagonism
virtual reality education module in reducing anxiety and increasing knowledge in patients with prostate cancer undergoing radiation therapy

Conditions: Prostate

Summary: this pilot clinical trial studies a virtual reality education module in reducing anxiety and increasing knowledge in patients with prostate cancer undergoing radiation therapy. a virtual reality education module may be useful in helping patients understand what they can expect to happen during their radiation treatments and help reduce stress relating to the radiation treatments.

primary objectives: i. to determine if a virtual reality education module for prostate cancer patients is effective in increasing patient comprehension and decreasing patient anxiety related to radiation treatments. secondary objectives: i. this pilot study could have implications for a broader patient base undergoing radiation therapy.

Eligibility criteria:
inclusion criteria: * english speaking males capable of giving informed consent * must be able to read english language * receiving pre-treatment cone beam and volumetric modulated arc therapy (vmat) for prostate cancer on the "a" or "b" treatment machines at the bodine center * must be able to walk two city blocks * must not have any auditory or visual deficits exclusion criteria: * if inclusion criteria are not met * previous radiation therapy treatment * employment in radiation oncology
a study to examine the effects of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus in healthy adults

Conditions: Hepatitis C

Summary: the purpose of this study is to evaluate the effect that telaprevir has on the pharmacokinetics of cyclosporine and tacrolimus. pharmacokinetics means how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body.


Eligibility criteria:
inclusion criteria: * healthy female (non-childbearing potential) or male subjects between 18 and 60 years of age (inclusive) * body mass index (bmi) from 18 to 30 kg/m2 (inclusive) at the screening visit and day 1, and weigh more than 50 kg at screening. exclusion criteria: * history of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject. * participated in a clinical study involving administration of either an investigational or a marketed drug within 2 months or 5 half-lives (whichever is longer) before the screening visit. * positive result for any of the following infectious disease tests: hepatitis b antigen, hepatitis c virus antibody, human immunodeficiency virus 1 antibody, or human immunodeficiency virus 2 antibody.

Keywords: vx-950
an epidemiological study to describe symptom control and impact of gastroesophageal reflux disease

Conditions: GERD

Summary: the purpose of this study is to examine patient's perspective of symptom control and impact of gastroesophageal reflux disease (gerd) on daily life.


Eligibility criteria:
inclusion criteria: * patients with gastroesophageal reflux disease -gerd (disease duration ≤3 years or newly diagnosed) that are currently not treated with a proton pump inhibitor, for whom the general practitioner (gp) has previously decided to initiate or change the tre * patients should be treated for gerd according to current practice (national guideline for treatment of dyspepsia in gp setting)

Keywords: gastroesophageal reflux disease (gerd)
hormones and physical exercise (hope) study

Conditions: Breast Cancer; Arthralgia

Summary: the investigators propose to examine 121 postmenopausal women diagnosed with hormone-receptor positive breast cancer who have been taking aromatase inhibitors (ai) for at least 6 months and are experiencing at least mild arthralgia originating during ai treatment, the yearlong effect of exercise vs. attention control (health education), and on toxic side effects of ai.

the investigators propose to examine, in 121 postmenopausal breast cancer survivors who have been taking an ai for at least 2 months and are currently experiencing at least mild arthralgia associated with ai use, the effect of a randomized controlled exercise intervention vs. attention control (health education) on severity of arthralgia, endocrine-related quality of life(qol), bone mineral density(bmd), and mediators/mechanisms influencing the effect of exercise on arthralgia severity. women will be randomized to a year long exercise program or attention control group. women randomized to exercise will participate in 150 min/wk of aerobic exercise and a twice-weekly strength training program. the investigators will conduct baseline, six-, and 12-month clinic visits, as well as a 3- and 9-month mailing to evaluate the effect of the intervention on study outcomes.

Eligibility criteria:
inclusion criteria: * postmenopausal women (defined as the surgical or natural absence of menstrual cycles for at least 1 year prior to breast cancer diagnosis). * 75 years or younger * ajcc stages i-iiic breast cancer * taking an ai for at least 2 months * currently experiencing at least mild arthralgia (= or \> 3 on the bpi) associated with ai use * physically able to exercise and physician consent to start an exercise program * sedentary activity pattern (\< 90 mins/week of moderate-to-vigorous intensity sports activity) within the past year and low fitness level * no more than one strength training session per week within the past year * agrees to be randomly assigned to either exercise or attention control * gives informed consent to participate in all study activities * able to come for baseline, 6-, and 12-month clinic visits and strength training sessions (6-month intervention study - able to come for baseline, 6-month clinic visits and strength training sessions). * mentally competent exclusion criteria: * lymphedema with self reported 'flare up' in the past 4 months
sirolimus as primary therapy for the treatment of chronic graft versus host disease

Conditions: Graft vs Host Disease; Blood and Marrow Transplant (BMT)

Summary: evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic graft versus host disease.

an open label study of sirolimus as primary therapy for the treatment of chronic gvhd following allogeneic bone marrow transplant

Eligibility criteria:
inclusion criteria:- active chronic gvhd * anc \> 1000/mm\^3 * therapeutic cyclosporine exclusion criteria:- uncontrolled systemic infection * elevated serum creatinine
impact of positive end maximum voluntary ventilation and dyspnea index in patients after valvular heart surgery

Conditions: Respiration Disorders

Summary: pulmonary mechanics are further disturbed after cardiothoracic surgery that manifests like restrictive pathology, which may persist for weeks to months postoperatively. this experimental aimed to investigate the efficacy of a positive end-expiratory pressure device on maximum expiratory pressure, maximum voluntary ventilation, and dyspnea index in patients who underwent valve surgery.

thirty male and female adolescent patients who underwent valve surgery aged 12-18 years old, recruited from the national heart institute enrolled in this experimental. they were assigned into two matched groups: experimental group consisted of 15 patients, received positive end-expiratory pressure (peep) with a mouthpiece in addition to routine chest physiotherapy (postural drainage, percussion, vibration, and deep breathing exercises). control group consisted of 15 patients, received routine chest physiotherapy alone. the program continued for four weeks.

Eligibility criteria:
inclusion criteria: * male patients * underwent valve surgery (repair or replacement) for mitral valve stenosis; * hemodynamically stable, * ages ranged from 12 to 18 years old- * bmi ranges from 18.5 to 24.9 * reduced mep, mvv and complaining from shortness of breath with exertion. exclusion criteria: * patients with previous cardiac surgery * congenital heart disease * neurological disorders * type1 diabetes mellitus * smoker * pacemaker implantation * atrial fibrillation * utilization of mechanical ventilation longer than 24 hours.
a dose-finding study of asp4070

Conditions: Rhinitis, Allergic, Seasonal

Summary: the objective of this study was to evaluate the efficacy, safety, and dose-response of asp4070 vaccinated in patients with cedar pollinosis.

subjects were vaccinated with asp4070 or placebo at 2 week intervals. clinical symptoms were evaluated after cedar pollen exposure in a chamber at 4, 8 and 12 weeks after the last vaccination to identify the timing of the onset of therapeutic effect.

Eligibility criteria:
inclusion criteria: * subject who has exhibited symptoms of cedar pollinosis, consisting of nasal symptoms (sneezing, nasal discharge or nasal obstruction) and eye symptoms (itchy eyes or watery eyes) during the pollen dispersal seasons in 2016 and 2017 * subject who is positive for the japanese red cedar (jrc) pollen-specific serum ige antibody test * at screening, subject whose score has worsened compared to baseline over 120 to 180 minutes after cedar pollen exposure in a chamber exclusion criteria: * subject who has positive the test result of serum ige antibody specific to other antigen than jrc pollen at screening * subject who has received specific immunotherapy (including desensitization therapy) for cedar pollinosis in the past * subject who has received specific or non-specific immunotherapy within 5 years prior to screening * subject who has received laser therapy or surgery for the treatment of nasal symptoms within 3 years prior to screening. * subject who has a history of allergic reactions such as anaphylactic shock and exanthema generalized caused by food and/or medical products in the past * subject who has a positive test result for hepatitis b surface (hbs) antigen or anti-hepatitis c virus (hcv) antibody * subject who has nasal disease that may interfere with the evaluation * subject who has autoimmune disease or other serious primary disease * subject who was diagnosed with immunodeficiency in the past * subject who has a complication of seasonal allergic rhinitis (due to allergens other than japanese cedars or cypress), perennial allergic rhinitis, rhinitis medicamentosa, or non-allergic rhinitis that requires medical treatment * subject who has a complication of cardiovascular disease * subject who has a complication of hepatic disease * subject who has a complication of renal disease * subject who has a complication of respiratory disease * subject has a complication of malignant tumor or has been diagnosed with or has received treatment for malignant tumor within 5 years prior to the first vaccination of the study drug * subject who was diagnosed with schizophrenia, other mental conditions * subject who has a complication that may have an impact on the results of the local or systemic reaction * subject who has received a vaccination of cry j 2-lamp vaccine * subject who has participated in a clinical study of asp4070 and received a vaccination of the study drug.

Keywords: cedar pollinosis asp4070 dna plasmid vaccine
effects of exercise training in survivors of lymphoma

Conditions: Lymphoma; Physical Exercise; Cardiotoxicity; Cardiovascular Diseases; Chemotherapeutic Toxicity

Summary: this study aims to compare the effects of aerobic exercise with or without addition of resistance exercise to usual care in individuals treated with anthracyclines for lymphomas and to compare exercise effects to age- and sex-matched individuals with no prior history of malignant diseases.

in this study, a comparison of the exercise effects between individuals previously treated for specific lymphoma diagnoses and individuals with no history of cancer will be conducted. therefore, in addition to a randomized controlled trial in individuals with a previous lymphoma diagnosis (i.e., exercise groups and a non-exercising control group), a reference group comprising age- and sex-matched individuals with no history of a cancer diagnosis will also be included. participants in the reference group will undergo the same exercise intervention as the aerobic exercise group. this study recruits through invitation only. the primary endpoint in this study is the change in cardiorespiratory fitness, assessed as vo2peak. secondary endpoints include common risk factors for cardiovascular disease and cardiometabolic health, other variables derived from the cardiopulmonary exercise test and lung function assessments, and muscle cellular endpoints from muscle biopsies obtained from m. vastus lateralis, in addition to patient-reported outcomes.

Eligibility criteria:
inclusion criteria lymphoma participants: * listed in relevant registers * confirmed lymphoma diagnosis (i.e., hodgkin lymphoma and aggressive non-hodgkin lymphoma) * completed treatment in the past two to five years without relapse or second cancer * previous anthracycline treatment with or without mediastinal radiation * no severe cancer-related fatigue (per self-report) inclusion criteria lymphoma participants and non-cancer reference group: * currently not performing \>75 minutes/week of aerobic exercise * willing and able to adhere to all study procedures. exclusion criteria lymphoma participants: * relapse since diagnosis * a history, or current presence, of another diagnosis of invasive cancer of any kind exclusion criteria lymphoma participants and non-cancer reference group: * presence of any uncontrolled- or recent cardiovascular disease * has undergone heart surgery * uses a pacemaker * pregnancy * unable to read and understand swedish (applicable for the swedish site only) * unable to read and understand norwegian (applicable for the norwegian site) * any physical or mental health condition restricting adherence to study protocol
avatrombopag for the treatment of thrombocytopenia in pediatric subjects with immune thrombocytopenia for ≥6 months

Conditions: Immune Thrombocytopenia

Summary: a phase 3b study to evaluate the efficacy and safety of avatrombopag for the treatment of thrombocytopenia in pediatric subjects with immune thrombocytopenia for ≥6 months

subjects will be randomized in to blinded therapy of avatrombopag or placebo in a 3:1 ratio for a period of 12 weeks. subjects who complete the 12 week treatment period and are eligible may continue to the open label extension phase which will last 2 years.

Eligibility criteria:
inclusion criteria: * male or female participants ≥1 and \<18 years of age at screening and baseline with a diagnosis of primary itp for ≥6 months duration and has had an insufficient response to a previous treatment, in the opinion of the investigator. * participant has an average of 2 platelet counts \ 35×10\^9/l in the screening period exclusion criteria: * participants must not have a known history of secondary itp, any history of arterial or venous thrombosis, including partial or complete thrombosis, known inherited thrombocytopenia, a history of myelodysplastic syndrome (mds) or known history of congenital heart abnormalities or arrhythmias.

Keywords: itp
ct-guided radioactive i-125 seeds implantation for early stage lung cancer

Conditions: Early Stage Non-small Cell Lung Cancer

Summary: this study observes the efficacy and side effects of ct-guided radioactive iodine-125 seed brachytherapy in inoperable early stage non-small cell lung cancer retrospectively, and analyzes the influence of clinical and dosimetric factors on the outcomes.

radioactive iodine-125 seed brachytherapy is a conventional treatment in peking university third hospital. radioactive iodine-125 seed brachytherapy is the implantation of iodine-125 seed into tumors.the radioactive iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. this study collects the data of patients with early stage (stage i-ii, n0) non-small cell lung cancer who underwent ct-guided radioactive iodine-125 seed implantation from 2010 to 2018. the investigators evaluate the dose that covers 90% target volume(d90) and other parameters after the implantation. the efficacy and adverse effects were observed. local control(lc) time and overall survival(os) time are evaluated.

Eligibility criteria:
inclusion criteria: * histological proven non-small cell lung cancer * uicc (union for international cancer control) stage was t1-3n0m0 (stage ia-iib) * inoperable and ct-guided radioactive iodine-125 seeds brachytherapy was used as the initial treatment without external beam radiotherapy exclusion criteria: * actual dose of covers 90% target volume (d90) less than 100 gy in postoperative validation * case information and/or follow-up information was unavailable

Keywords: radioactive iodine-125 seeds implantation non-small cell lung cancer early stage
study of the impact of time of vaccination on response to influenza vaccine in patients with chronic renal failure

Conditions: Vaccination; Infection

Summary: immune response to influenza vaccine in patients with chronic renal insufficiency.

seasonal influenza vaccination is recommended for patients with chronic renal insufficiency, as influenza is responsible for significant morbidity and mortality in this immunocompromised population. however, the immune response to this vaccination is limited in this population. there are currently no recommendations concerning the timing of influenza vaccine in the general population or in immunocompromised patients. in this context, recent studies have shown that the time of vaccination can have an impact on vaccine efficacy. this is the case for bcg, influenza and covid vaccinations. on this basis, our main hypothesis is that the administration of influenza vaccine to patients with chronic kidney failure is more effective in the morning than in the evening.

Eligibility criteria:
inclusion criteria: * chronic renal failure patient at stage 4 or 5 (i.e. estimated gfr \< 30ml/min/1.73m2); or dialysis patient; or renal transplant patient regardless of gfr; * age ≥ 18 years; * indication for influenza vaccination; * express free and informed consent. exclusion criteria: * known hypersensitivity to influenza vaccine or egg proteins; * previous influenza vaccination for the current season; * current infection; * current acute illness; * treatments with a major impact on vaccine response: * treatment of rejection within the previous 3 months; * renal transplantation with induction performed within the previous 6 months; * immunosuppressive treatment including ctla4 agonist, complement inhibitor, anti-cd20; * treatments that may distort the serological response: polyvalent immunoglobulin infusion within the preceding 3 months; * vulnerable persons (minors, adults under guardianship or trusteeship, persons deprived of their liberty, persons unable to speak french); * subjects not affiliated to social security.

Keywords: influenza chronic renal insufficiency vaccination